Otsuka's Zipalertinib Plus Chemotherapy Hits Key Goal in Lung Cancer Trial

Otsuka Holdings has announced that its investigational drug zipalertinib, when combined with chemotherapy, achieved the primary endpoint of progression-free survival (PFS) in a planned interim analysis of the Phase 3 REZILIENT3 trial.

The company disclosed the development on August 13, marking a significant milestone in the clinical evaluation of the therapy. The REZILIENT3 study is designed to assess the efficacy and safety of the combination regimen in a specific patient population.

While the company did not release detailed efficacy data or the magnitude of the benefit in its brief statement, meeting the primary PFS endpoint at an interim analysis is generally considered a positive signal for the treatment's potential. Further details from the analysis are expected to be presented at upcoming medical conferences or published in peer-reviewed journals.

Zipalertinib is being developed as a targeted therapy, and the positive interim result adds to the growing body of evidence supporting its use in combination with standard chemotherapy. The announcement is likely to be followed by discussions with regulatory authorities regarding next steps in the drug's development pathway.